Business
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS Canada NewsWi...
About this update from Medicure Inc.
[{"type":"text","content":"\n \n \n \n MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n WINNIPEG, MB\n \n \n ,\n \n \n Feb. 1, 2023\n \n \n /CNW/ - Medicure Inc. (\"\n \n Medicure\n \n \" or the \"\n \n Company\n \n \") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in\n \n the United States\n \n market, announced today that\n \n Gerald McDole\n \n , a member of the Board of Directors, has resigned from his position, effective\n \n January 31, 2023\n \n . Mr. McDole was originally appointed a director on\n \n January 16, 2004\n \n .\n \n \n \"On behalf of the Board and senior leadership team, I would like to thank Gerry for his long-standing years of service to the Company, stated\n \n Albert Friesen\n \n ,\" Chair of Medicure's Board of Directors.  \"His experienced guidance and reasoned strategic insights greatly benefited Medicure throughout the years and we were blessed to have someone of Gerry's character and integrity in a governance position.\"\n \n \n The Company also announces that it has granted stock options (the \"Options\") to certain directors, officers and employees of the Company to purchase a total of 1,205,000 common shares at a price of\n \n $1.25\n \n per common share. The Options are exercisable for a period of ten years and have been granted in accordance with the terms of the Company's current stock option plan. The grant of Options is subject to the approval of the TSX Venture Exchange.\n \n \n \n About Medicure Inc.\n \n \n \n Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT\n \n ®\n \n (tirofiban hydrochloride) injection and ZYPITAMAG\n \n ®\n \n (pitavastatin) tablets in\n \n the United States\n \n , where they are sold through the Company's U.S. subsidiary, Med...